HADI M. YASSINE

Cituota

	Visi	Nuo 2019
Šaltiniai	16907	14926
h-rodyklė	61	58
i10-rodyklė	168	160

4800

2400

1200

3600

200920102011201220132014201520162017201820192020202120222023202442 54 56 98 150 179 189 330 346 439 519 1315 2957 4786 4001 1231

Viešas pasiekiamumas

Peržiūrėti viską

25 straipsniai

0 straipsnių

pasiekiami

nepasiekiami

Pagal finansavimo įpareigojimus

Bendraautoriai

Gheyath K. NasrallahAssociate Professor of Biomedical Science, College of Health Sciences, QU health, Qatar UniversityPatvirtintas el. paštas qu.edu.qa
Hebah Al KhatibResearch associate, Qatar UniversityPatvirtintas el. paštas qu.edu.qa
Maria K. SmattiQatar UniversityPatvirtintas el. paštas qu.edu.qa
Masaru KanekiyoVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of HealthPatvirtintas el. paštas nih.gov
Duaa Al-SadeqPhD candidate, Qatar UniversityPatvirtintas el. paštas qu.edu.qa
nadin younesPhD Candidate, Qatar UniversityPatvirtintas el. paštas qu.edu.qa
Nahla O EltaiQatar UniversityPatvirtintas el. paštas qu.edu.qa
Kizzmekia S. CorbettVaccine Research Center, NIAID, NIHPatvirtintas el. paštas nih.gov
Shilu MathewBRCPatvirtintas el. paštas qu.edu.qa
Syed M. MoinSenior Scientist, National Institutes of Health, Bethesda, USAPatvirtintas el. paštas nih.gov
M. Gordon Joyce, PhDChief, Structural Biology, HJF, WRAIRPatvirtintas el. paštas eidresearch.org
Adrian B McDermottChief, Vaccine Immunology Program, Vaccine Research Center, NIAID-NIHPatvirtintas el. paštas nih.gov
Jason S. McLellanProfessor of Molecular BiosciencesPatvirtintas el. paštas austin.utexas.edu
Adam WheatleyUniversity of MelbournePatvirtintas el. paštas unimelb.edu.au
elmoubasher faragMinistry of public health -QatarPatvirtintas el. paštas moph.gov.qa
Mutasem El-FadelAmerican University of BeirutPatvirtintas el. paštas aub.edu.lb
Steve HarakehKing Fahd Medical Research Center, King Abdulaziz UniversityPatvirtintas el. paštas kau.edu.sa
Nianshuang Wang (王年爽)Research FellowPatvirtintas el. paštas utexas.edu
Jesper PallesenIndiana University BloomingtonPatvirtintas el. paštas pallesen.info
Hannah L TurnerThe Scripps Research InstitutePatvirtintas el. paštas scripps.edu

Stebėti

HADI M. YASSINE

Section Head of Research, Associate Professor of Infectious Diseases, IBC chair, Qatar University

Patvirtintas el. paštas QU.edu.qa

Virology Immunology and Vaccinology


Pavadinimas Rūšiuoti pagal šaltinius Rūšiuoti pagal metus Rūšiuoti pagal pavadinimą	Cituota Cituota	Metai
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B. 1.1. 7 and B. 1.351 Variants LJ Abu-Raddad, H Chemaitelly, AA Butt New England Journal of Medicine 385 (2), 187-189, 2021	1090	2021
Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar H Chemaitelly, P Tang, MR Hasan, S AlMukdad, HM Yassine, ... New England Journal of Medicine 385 (24), e83, 2021	857	2021
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies M Kanekiyo, CJ Wei, HM Yassine, PM McTamney, JC Boyington, ... Nature 499 (7456), 102-106, 2013	825	2013
Pre-fusion structure of a human coronavirus spike protein RN Kirchdoerfer, CA Cottrell, N Wang, J Pallesen, HM Yassine, HL Turner, ... Nature 531 (7592), 118-121, 2016	817	2016
Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection HM Yassine, JC Boyington, PM McTamney, CJ Wei, M Kanekiyo, ... Nature medicine 21 (9), 1065-1070, 2015	647	2015
Effects of previous infection and vaccination on symptomatic omicron infections HN Altarawneh, H Chemaitelly, HH Ayoub, P Tang, MR Hasan, ... New England Journal of Medicine 387 (1), 21-34, 2022	454	2022
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar P Tang, MR Hasan, H Chemaitelly, HM Yassine, FM Benslimane, ... Nature medicine 27 (12), 2136-2143, 2021	449	2021
Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms MK Smatti, FS Cyprian, GK Nasrallah, AA Al Thani, RO Almishal, ... Viruses 11 (8), 762, 2019	439	2019
Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2 N Younes, DW Al-Sadeq, H Al-Jighefee, S Younes, O Al-Jamal, HI Daas, ... Viruses 12 (6), 582, 2020	425	2020
Protection against the Omicron variant from previous SARS-CoV-2 infection HN Altarawneh, H Chemaitelly, MR Hasan, HH Ayoub, S Qassim, ... New England Journal of Medicine 386 (13), 1288-1290, 2022	413	2022
mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar H Chemaitelly, HM Yassine, FM Benslimane, HA Al Khatib, P Tang, ... Nature medicine 27 (9), 1614-1621, 2021	403	2021
Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar LJ Abu-Raddad, H Chemaitelly, HH Ayoub, S AlMukdad, HM Yassine, ... New England Journal of Medicine 386 (19), 1804-1816, 2022	367	2022
Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera JO Ngwuta, M Chen, K Modjarrad, MG Joyce, M Kanekiyo, A Kumar, ... Science translational medicine 7 (309), 309ra162-309ra162, 2015	366	2015
Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines Q Fernandes, VP Inchakalody, M Merhi, S Mestiri, N Taib, ... Annals of medicine 54 (1), 524-540, 2022	356	2022
Evaluation of candidate vaccine approaches for MERS-CoV L Wang, W Shi, MG Joyce, K Modjarrad, Y Zhang, K Leung, CR Lees, ... Nature communications 6 (1), 7712, 2015	319	2015
Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses MG Joyce, AK Wheatley, PV Thomas, GY Chuang, C Soto, RT Bailer, ... Cell 166 (3), 609-623, 2016	302	2016
Structural and genetic basis for development of broadly neutralizing influenza antibodies D Lingwood, PM McTamney, HM Yassine, JRR Whittle, X Guo, ... Nature 489 (7417), 566-570, 2012	287	2012
Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses M Kanekiyo, MG Joyce, RA Gillespie, JR Gallagher, SF Andrews, ... Nature immunology 20 (3), 362-372, 2019	240	2019
Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting Clinical Infectious Diseases, 2020	239*	2020
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants in Qatar H Chemaitelly, HH Ayoub, S AlMukdad, P Coyle, P Tang, HM Yassine, ... Nature communications 13 (1), 3082, 2022	221	2022

Sistema negali atlikti operacijos. Bandykite vėliau dar kartą.

Straipsniai 1–20

Šaltinių per metus

Dubliuoti šaltiniai

Sujungti šaltiniai

Pridėti bendraautoriusBendraautoriai

Stebėti

Cituota

Bendraautoriai